Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to describe the prevalence of additional autoimmune diseases and their specific antibodies at type 1 diabetes (T1D) diagnosis, and their incidence rate during follow-up, for children and adolescents. It also aims to describe the characteristics of the pediatric cohort followed since 2014 for type 1 diabetes by one of France's centers of reference for paediatric diabetes.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No intervention. | Other | There is no intervention needed. It is a retrospective cohort. The usual follow-up of type 1 diabetes is studied from its beginning to the last news of the patient. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of additional autoimmune diseases at type 1 diabetes diagnosis | Will be studied the additional autoimmune diseases to type 1 diabetes listed in the 2018 ISPAD recommendations | up to 3 weeks after type 1 diabetes diagnosis |
| Type of additional autoimmune diseases at type 1 diabetes diagnosis | Will be studied the additional autoimmune diseases to type 1 diabetes listed in the 2018 ISPAD recommendations | up to 3 weeks after type 1 diabetes diagnosis |
| Measure | Description | Time Frame |
|---|---|---|
| Characteristics of patients, if additional autoimmune disease is present or absent | Family and personal history, biological, serological, anthropometrical characteristics at type 1 diabetes diagnostic | up to 3 weeks after type 1 diabetes diagnosis |
| Occurence or non-occurence of at least one additional autoimmune diseases during follow-up |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Every patient followed for type 1 diabetes at the Children's Hospital of Nancy, France, between 2014-01-01 and 2021-02-01.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Carole LEGAGNEUR, MD | Centre Hospitalo-Universitaire de Nancy, Hôpital d'Enfants de Brabois | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpital d'Enfants de Brabois | Vandœuvre-lès-Nancy | Lorraine | 54500 | France |
Not provided
Not provided
Not provided
Not provided
Will be studied the additional autoimmune diseases to type 1 diabetes listed in the 2018 ISPAD recommendations |
| From type 1 diabetes diagnostic to last news date, an average of 3 years |
| Occurence or non-occurence of each type of additional autoimmune disease during follow-up | Will be studied the additional autoimmune diseases to type 1 diabetes listed in the 2018 ISPAD recommendations, in this outcome studied each one separately | From type 1 diabetes diagnostic to last news date, an average of 3 years |
| Presence of antibodies specific to an additional autoimmune disease at type 1 diabetes diagnostic | Antibodies detected in the serum, antibodies specific to the following autoimmune diseases : Hashimoto (Thyroid peroxidase antibodies, and/or thyroglobulin antibodies) Graves disease (TRAK), coeliac disease (anti-tissue transglutaminase (tTG) antibodies,endomysial antibodies (EMA)), Addison disease ( adrenal antibodies ), autoimmune gastritis (parietal cell antibodies) | up to 3 weeks after type 1 diabetes diagnosis |
| Characteristics of patients, if at least one type of antibodies specific to an autoimmune disease is present or absent at type 1 diabetes diagnostic | Family and personal history, biological, serological, anthropometrical characteristics at type 1 diabetes diagnostic | up to 3 weeks after type 1 diabetes diagnosis |
| Characteristics of patients, for each type of antibodies specific to an autoimmune disease, present or absent at type 1 diabetes diagnostic | Family and personal history, biological, serological, anthropometrical characteristics at type 1 diabetes diagnostic | up to 3 weeks after type 1 diabetes diagnosis |
| Occurence or non-occurence of at least one type of antibody specific to an additional autoimmune disease | Antibodies detected in the serum, antibodies specific to the following autoimmune diseases : Hashimoto (Thyroid peroxidase antibodies, and/or thyroglobulin antibodies) Graves disease (TRAK), coeliac disease (anti-tissue transglutaminase (tTG) antibodies,endomysial antibodies (EMA)), Addison disease ( adrenal antibodies ), autoimmune gastritis (parietal cell antibodies) | From type 1 diabetes diagnosis to last news date, from 1 to 6 years |
| Occurence or non-occurence of antibodies specific to each additional autoimmune disease listed in outcome 5 | Antibodies detected in the serum, antibodies specific to the following autoimmune diseases : Hashimoto (Thyroid peroxidase antibodies, and/or thyroglobulin antibodies) Graves disease (TRAK), coeliac disease (anti-tissue transglutaminase (tTG) antibodies,endomysial antibodies (EMA)), Addison disease ( adrenal antibodies ), autoimmune gastritis (parietal cell antibodies) | From type 1 diabetes diagnosis to last news date, from 1 to 6 years |
| Description of the characteristics of all the patients followed in our cohort of pediatric type 1 diabetes | Family and personal history, biological, serological, anthropometrical characteristics at type 1 diabetes diagnostic, presence of antibodies specific to an additional autoimmune disease, and occurence of additional autoimmune diseases | Up to 3 weeks after type 1 diabetes diagnosis |
| Description of the autoimmune characteristics of all the patients followed in our cohort of pediatric type 1 diabetes | presence of antibodies specific to an additional autoimmune disease, and occurence of additional autoimmune diseases | during follow-up : From type 1 diabetes diagnosis to last news date, from 1 to 6 years |
| If detection of antibodies specific to an additional autoimmune disease : delay between detection of these antibodies and diagnosis of the corresponding autoimmune disease | Antibodies detected in the serum, antibodies specific to the following autoimmune diseases : Hashimoto (Thyroid peroxidase antibodies, and/or thyroglobulin antibodies) Graves disease (TRAK), coeliac disease (anti-tissue transglutaminase (tTG) antibodies,endomysial antibodies (EMA)), Addison disease ( adrenal antibodies ), autoimmune gastritis (parietal cell antibodies) | From type 1 diabetes diagnosis to last news date, from 1 to 6 years |
| If patient diagnosed with Hashimoto when type 1 diabetes is diagnosed, proportion of patients with thyroid dysfunction | Thyroid dysfunction : hormonal dysfunction associated to Hashimoto | Up to 3 weeks after type 1 diabetes diagnosis |
| Occurence of thyroid dysfunction in patients with type 1 diabetes and Hashimoto | Occurence during type 1 diabetes follow-up of thyroid dysfunction in patients with Hashimoto | From type 1 diabetes diagnosis to last news date, from 1 to 6 years |
| Proportion of patients with thyroid dysfunction due to Hashimoto needing a specific treatment | Up to 3 weeks after type 1 diabetes diagnosis |
| Occurence of specific treatment onset in patients followed for type 1 diabetes with thyroid dysfunction due to Hashimoto | From type 1 diabetes diagnosis to last news date, from 1 to 6 years |
| ID | Term |
|---|---|
| D003922 | Diabetes Mellitus, Type 1 |
| D001327 | Autoimmune Diseases |
| D050031 | Hashimoto Disease |
| D006111 | Graves Disease |
| D002446 | Celiac Disease |
| D000224 | Addison Disease |
| D014820 | Vitiligo |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D007154 | Immune System Diseases |
| D013967 | Thyroiditis, Autoimmune |
| D013966 | Thyroiditis |
| D013959 | Thyroid Diseases |
| D005094 | Exophthalmos |
| D009916 | Orbital Diseases |
| D005128 | Eye Diseases |
| D006042 | Goiter |
| D006980 | Hyperthyroidism |
| D008286 | Malabsorption Syndromes |
| D007410 | Intestinal Diseases |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| D000309 | Adrenal Insufficiency |
| D000307 | Adrenal Gland Diseases |
| D017496 | Hypopigmentation |
| D010859 | Pigmentation Disorders |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided